AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

Yarely M. Salinas-Vera, Laurence A. Marchat, Dolores Gallardo-Rincón, Erika Ruiz-García, Horacio Astudillo-De la Vega, Raquel Echavarría-Zepeda, César López-Camarillo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

© 2019 Spandidos Publications. All rights reserved. Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.
Original languageAmerican English
Pages (from-to)657-670
Number of pages589
JournalInternational Journal of Molecular Medicine
DOIs
StatePublished - 1 Feb 2019

Fingerprint

MicroRNAs
Neoplasms
MAP Kinase Kinase 3
Hypoxia-Inducible Factor 1
Small Untranslated RNA
Angiogenesis Inhibitors
1-Phosphatidylinositol 4-Kinase
Fibroblast Growth Factors
Platelet-Derived Growth Factor
Transforming Growth Factors
Metalloproteases
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Publications
Intercellular Signaling Peptides and Proteins
Cytokines
Neoplasm Metastasis
Drug Therapy
Therapeutics
Growth

Cite this

Salinas-Vera, Y. M., Marchat, L. A., Gallardo-Rincón, D., Ruiz-García, E., Astudillo-De la Vega, H., Echavarría-Zepeda, R., & López-Camarillo, C. (2019). AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). International Journal of Molecular Medicine, 657-670. https://doi.org/10.3892/ijmm.2018.4003
Salinas-Vera, Yarely M. ; Marchat, Laurence A. ; Gallardo-Rincón, Dolores ; Ruiz-García, Erika ; Astudillo-De la Vega, Horacio ; Echavarría-Zepeda, Raquel ; López-Camarillo, César. / AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). In: International Journal of Molecular Medicine. 2019 ; pp. 657-670.
@article{f36aa653d89049789dac7ec99ec57142,
title = "AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)",
abstract = "{\circledC} 2019 Spandidos Publications. All rights reserved. Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.",
author = "Salinas-Vera, {Yarely M.} and Marchat, {Laurence A.} and Dolores Gallardo-Rinc{\'o}n and Erika Ruiz-Garc{\'i}a and {Astudillo-De la Vega}, Horacio and Raquel Echavarr{\'i}a-Zepeda and C{\'e}sar L{\'o}pez-Camarillo",
year = "2019",
month = "2",
day = "1",
doi = "10.3892/ijmm.2018.4003",
language = "American English",
pages = "657--670",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",

}

Salinas-Vera, YM, Marchat, LA, Gallardo-Rincón, D, Ruiz-García, E, Astudillo-De la Vega, H, Echavarría-Zepeda, R & López-Camarillo, C 2019, 'AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)' International Journal of Molecular Medicine, pp. 657-670. https://doi.org/10.3892/ijmm.2018.4003

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). / Salinas-Vera, Yarely M.; Marchat, Laurence A.; Gallardo-Rincón, Dolores; Ruiz-García, Erika; Astudillo-De la Vega, Horacio; Echavarría-Zepeda, Raquel; López-Camarillo, César.

In: International Journal of Molecular Medicine, 01.02.2019, p. 657-670.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

AU - Salinas-Vera, Yarely M.

AU - Marchat, Laurence A.

AU - Gallardo-Rincón, Dolores

AU - Ruiz-García, Erika

AU - Astudillo-De la Vega, Horacio

AU - Echavarría-Zepeda, Raquel

AU - López-Camarillo, César

PY - 2019/2/1

Y1 - 2019/2/1

N2 - © 2019 Spandidos Publications. All rights reserved. Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.

AB - © 2019 Spandidos Publications. All rights reserved. Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060058753&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85060058753&origin=inward

U2 - 10.3892/ijmm.2018.4003

DO - 10.3892/ijmm.2018.4003

M3 - Article

SP - 657

EP - 670

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

ER -

Salinas-Vera YM, Marchat LA, Gallardo-Rincón D, Ruiz-García E, Astudillo-De la Vega H, Echavarría-Zepeda R et al. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). International Journal of Molecular Medicine. 2019 Feb 1;657-670. https://doi.org/10.3892/ijmm.2018.4003